Yes, but you should carry the prescription label and a copy of the treatment plan. Some countries may ask for documentation of ongoing therapy for leprosy, so having the prescribing information handy can avoid customs delays.
The pigmentation typically appears as a reddish-brown to black shadow on the skin, especially on exposed areas. In many cases the colour persists for months to years after discontinuation, and complete reversal is uncommon.
Lamprene is the primary brand available in the UK. Generic versions may be marketed under the ingredient name “clofazimine” but must meet the same MHRA standards for safety and efficacy.
Clinical improvement in leprosy lesions usually becomes noticeable after several weeks of consistent therapy, although the anti-mycobacterial effect begins soon after the first dose.
Clofazimine’s absorption is not significantly affected by antacids, but taking the tablet with food is recommended to minimise gastrointestinal upset.
Clofazimine is mainly excreted via the feces, and renal impairment does not usually require dose adjustment. Nevertheless, clinicians should monitor for any unusual side effects.
Severe abdominal pain could indicate enteropathy, a rare but serious side effect. Seek medical attention promptly; the drug may need to be stopped.
No clinically significant interaction has been documented between clofazimine and hormonal contraceptives, but it is prudent to discuss all medications with a healthcare professional.
Both the brand-name Lamprene and generic clofazimine are subject to the NHS pricing structure. Prices may vary slightly based on pharmacy contracts, but the cost difference is generally modest.
Clofazimine does not usually affect coagulation, but pre-operative assessment should include a review of liver function and any concurrent medications. Inform the surgical team of all drugs you are taking.
Lamprene is a brand name for the antibiotic clofazimine, supplied as a 50 mg oral pill. It belongs to the class of anti-mycobacterial agents and is primarily used in the treatment of leprosy (Hansen’s disease). In the United Kingdom, Lamprene is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The tablet is taken by mouth and must be stored at room temperature away from moisture.
Clofazimine exerts its effect by binding to bacterial DNA and interrupting the replication of mycobacteria. It also has anti-inflammatory properties that help control immune-mediated complications of leprosy. After oral ingestion, the drug is slowly absorbed, and its bioavailability is modest because a large proportion remains in the gastrointestinal tract. Clofazimine is extensively distributed to skin and fatty tissues, which explains the characteristic skin colour changes seen with therapy. The drug is metabolised in the liver and eliminated mainly in the faeces.
These indications are approved by the MHRA and follow World Health Organization (WHO) recommendations for multidrug therapy in leprosy. Clofazimine is not approved for routine use in other bacterial infections.
This article provides educational information about Lamprene and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
